乳癌診斷市場規模、佔有率和成長分析（按類型、產品、癌症類型、應用、最終用戶和地區分類）—產業預測，2026-2033年

預計到 2024 年，乳癌診斷市場規模將達到 60.4 億美元，到 2025 年將達到 65.1 億美元，到 2033 年將達到 118.7 億美元，在預測期（2026-2033 年）內，複合年成長率為 7.8%。

由於早期乳癌往往缺乏症狀，因此迫切需要創新解決方案，這推動了乳癌診斷市場快速發展。各公司正擴大利用人工智慧 (AI) 技術來提高檢測和診斷的準確性，例如，一些新型 AI 驅動系統正在尋求監管部門的核准。將 AI 整合到各種成像模式中，為醫院和支付方提供了更經濟的選擇。私人診斷中心的興起主要是由於對影像服務的需求不斷成長以及公立醫院面臨的種種限制。此外，發展中地區擴大採用翻新診斷設備，將其作為經濟有效的策略。行業領導者正在推動翻新系統的廣泛應用，以提高高品質診斷服務的可及性，並確保更好的患者照護。

乳癌診斷市場促進因素

乳癌診斷市場主要受持續的技術創新所驅動，包括尖端影像技術、分子診斷方法和生物標記檢測。這些創新顯著提高了乳癌檢測和診斷的準確性和效率。隨著這些先進診斷工具的普及和有效性不斷提高，其應用也日益廣泛，推動了市場顯著成長。這些技術的不斷發展不僅改善了患者的治療效果，也提高了醫療保健產業對可靠診斷解決方案的認知和需求，進一步促進了市場擴張。

乳癌診斷市場面臨的限制因素

與乳癌相關的文化觀念和社會污名可能會阻礙女性接受必要的篩檢和診斷程序。這種猶豫會對疾病的早期發現率和及時診斷產生重大影響。許多女性可能因為羞恥感或害怕社會污名而放棄利用現有的醫療保健服務。這會阻礙提高公眾意識、推廣定期篩檢的努力，最終降低乳癌診斷的整體有效性，並延遲能夠改善患者預後的重要干預措施。

乳癌診斷市場趨勢

乳癌診斷市場正加速向液態生物檢體轉型。液體活體組織切片無創技術，可分析血液樣本中的循環性腫瘤細胞和遊離DNA。這項創新技術因其早期檢測的潛力以及有效監測治療反應的能力而迅速受到關注，並成為傳統組織切片檢查的重要替代方案。液態生物檢體正在改變乳癌診斷的格局，隨著醫療服務提供者和患者尋求創傷更小、效率更高的診斷方案，液體活體組織切片也刺激了相關研究和投資。這一趨勢預示著癌症治療正朝著個人化醫療和改進的患者管理策略邁出重要一步。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究
• 技術進步

全球乳癌診斷市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 影像診斷
  • 乳房X光檢查
  • MRI
  • 超音波
  • PET/CT
• 切片檢查
• 基因組檢測
• 血液檢查
• 其他

全球乳癌診斷市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 基於平台的產品
  • 次世代定序
  • 微陣列
  • PCR
  • 其他
• 設備類產品
  • 影像
  • 切片檢查

全球乳癌診斷市場規模（按癌症類型和複合年成長率分類）（2026-2033 年）

• 乳管原位癌
• 浸潤性乳管癌
• 發炎性乳癌
• 轉移性乳癌

全球乳癌診斷市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 篩檢
• 診斷和預後
• 預後診斷
• 研究
• 其他

全球乳癌診斷市場規模（按最終用戶和複合年成長率分類）（2026-2033 年）

• 醫院和診所
• 診斷中心
• 醫療檢查室
• 其他

全球乳癌診斷市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Hologic（USA）
• Natera（USA）
• Siemens Healthineers（Germany）
• Leica Biosystems（Germany）（Parent company：Danaher Corporation）
• Roche Diagnostics（Switzerland）
• GE Healthcare（USA）
• Philips Healthcare（Netherlands）
• Abbott Laboratories（USA）
• Thermo Fisher Scientific（USA）
• Becton, Dickinson and Company（USA）
• Agilent Technologies（USA）
• Illumina（USA）
• PerkinElmer（USA）
• Qiagen（Germany）
• Bio-Rad Laboratories（USA）
• Cepheid（USA）（Parent company：Danaher Corporation）
• Myriad Genetics（USA）
• Fujifilm Holdings Corporation（Japan）
• Canon Medical Systems Corporation（Japan）
• Hitachi Medical Systems（Japan）

結論與建議

Breast Cancer Diagnostics Market size was valued at USD 6.04 Billion in 2024 and is poised to grow from USD 6.51 Billion in 2025 to USD 11.87 Billion by 2033, growing at a CAGR of 7.8% during the forecast period (2026-2033).

The breast cancer diagnostics market is evolving rapidly, driven by the pressing need for innovative solutions due to the often asymptomatic nature of early-stage breast cancer. Companies are increasingly leveraging artificial intelligence (AI) technologies to improve detection and diagnostic accuracy, with a notable example being a new AI-driven system aiming for regulatory approval. The integration of AI across diverse imaging modalities presents hospitals and payers with more economical options. The rise of private diagnostic centers is largely influenced by the growing demand for imaging services and the constraints faced by public hospitals. Additionally, in developing regions, the adoption of refurbished diagnostic equipment is gaining traction as a cost-effective strategy. Industry leaders are promoting refurbished systems to facilitate access to quality diagnostics, ensuring better patient care.

Top-down and bottom-up approaches were used to estimate and validate the size of the Breast Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Breast Cancer Diagnostics Market Segments Analysis

Global Breast Cancer Diagnostics Market is segmented by Type, Product, Cancer Type, Application, End-user and region. Based on Type, the market is segmented into Imaging, Biopsy, Genomic Tests, Blood Tests and Others. Based on Product, the market is segmented into Platform-based Products and Instrument-based Products. Based on Cancer Type, the market is segmented into Ductal carcinoma in situ, Invasive ductal carcinoma, Inflammatory breast cancer and Metastatic breast cancer. Based on Application, the market is segmented into Screening, Diagnostic and Predictive, Prognostic, Research and Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Centers, Medical Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Breast Cancer Diagnostics Market

The Breast Cancer Diagnostics market is being significantly propelled by ongoing technological advancements, including cutting-edge imaging techniques, molecular diagnostic methods, and biomarker assays. These innovations greatly enhance the accuracy and efficiency of breast cancer detection and diagnosis. As these sophisticated diagnostic tools become more accessible and effective, their adoption is increasing, leading to substantial growth in the market. The continuous evolution of these technologies not only improves patient outcomes but also fosters greater awareness and demand for reliable diagnostic solutions within the healthcare sector, further stimulating the market's expansion.

Restraints in the Breast Cancer Diagnostics Market

Cultural beliefs and prevalent social stigma related to breast cancer can deter women from pursuing necessary screening and diagnostic procedures. This reluctance can significantly affect the rates of early detection and timely diagnosis of the disease. Many women may feel ashamed or fearful of societal judgment, leading to a lack of engagement with available healthcare services. Consequently, such attitudes can hinder public awareness initiatives aimed at promoting regular check-ups and screenings, ultimately compromising the overall effectiveness of breast cancer diagnostics and delaying vital interventions that could improve outcomes for those affected by the disease.

Market Trends of the Breast Cancer Diagnostics Market

The breast cancer diagnostics market is increasingly leaning towards liquid biopsies, a non-invasive method that analyzes circulating tumor cells and cell-free DNA from blood samples. This innovative approach is rapidly gaining traction due to its potential for early detection and the ability to monitor treatment responses effectively, positioning it as a crucial alternative to traditional tissue biopsies. As healthcare providers and patients seek less invasive, more efficient diagnostic options, liquid biopsies are reshaping the landscape of breast cancer diagnostics, driving research and investment. This trend signals a significant shift towards personalized medicine and improved patient management strategies in oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Breast Cancer Diagnostics Market Size by Type & CAGR (2026-2033)

• Market Overview
• Imaging
  • Mammography
  • MRI
  • Ultrasound
  • PET/CT
• Biopsy
• Genomic Tests
• Blood Tests
• Others

Global Breast Cancer Diagnostics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Platform-based Products
  • Next-generation Sequencing
  • Microarrays
  • PCR
  • Others
• Instrument-based Products
  • Imaging
  • Biopsy

Global Breast Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Ductal carcinoma in situ
• Invasive ductal carcinoma
• Inflammatory breast cancer
• Metastatic breast cancer

Global Breast Cancer Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Screening
• Diagnostic and Predictive
• Prognostic
• Research
• Others

Global Breast Cancer Diagnostics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals & Clinics
• Diagnostic Centers
• Medical Laboratories
• Others

Global Breast Cancer Diagnostics Market Size & CAGR (2026-2033)

• North America (Type, Product, Cancer Type, Application, End-user)
  • US
  • Canada
• Europe (Type, Product, Cancer Type, Application, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Product, Cancer Type, Application, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Product, Cancer Type, Application, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Product, Cancer Type, Application, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Hologic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Leica Biosystems (Germany) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Philips Healthcare (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (USA) (Parent company: Danaher Corporation)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujifilm Holdings Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Canon Medical Systems Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hitachi Medical Systems (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations